|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-4.65/0.19
|
企业价值
136.70M
|
资产负债 |
每股账面净值
1.41
|
现金流量 |
现金流量率
0.41
|
损益表 |
收益
152.07M
|
每股收益
1.77
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/19 03:48 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |